CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00435-06v1
14/5/527    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J. G.
Right arrow Articles by Caulfield, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, J. G.
Right arrow Articles by Caulfield, M. J.
Clinical and Vaccine Immunology, May 2007, p. 527-537, Vol. 14, No. 5
1071-412X/07/$08.00+0     doi:10.1128/CVI.00435-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Establishing Acceptance Criteria for Cell-Mediated-Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal and Suboptimal Conditions{triangledown}

Jeffrey G. Smith,1* Heather R. Joseph,1 Tina Green,2 Jodie A. Field,1 Melissa Wooters,1 Robin M. Kaufhold,1 Joseph Antonello,2 and Michael J. Caulfield1

Vaccine and Biologics Research,1 Vaccine Biometrics, Merck Research Laboratories, 770 Sumneytown Pike, Merck and Co., Inc., West Point, Pennsylvania 194862

Received 17 November 2006/ Returned for modification 2 January 2007/ Accepted 8 March 2007

The enzyme-linked immunospot (ELISPOT) assay is a powerful tool for measuring antigen-specific cellular immune responses. The ability to use frozen peripheral blood mononuclear cells (PBMC) facilitates testing samples in multicenter clinical trials; however, unreliable ELISPOT responses may result if samples are not handled properly. Exposure of frozen PBMC to suboptimal storage temperature (–20°C) or repeated cycling between more optimal storage temperatures (less than –130°C and –70°C) reduced the quality of frozen PBMC, as assessed by cell viability and functional ELISPOT response measures. Cell viability as assessed by trypan blue dye exclusion was reduced, and the percentage of apoptotic cells, as determined by the Guava Nexin assay, was significantly increased after these events. The functional gamma interferon ELISPOT responses to phytohemagglutinin (PHA) mitogen, a CD4 T-cell-specific antigen (varicella-zoster virus), and a CD8 T-cell-specific antigen (pool containing known cytomegalovirus, Epstein-Barr virus, and influenza virus peptides) were all significantly reduced after suboptimal storage events. However, for a given suboptimal storage event, the magnitude of the reduction varied between individuals and even among aliquots within an individual bleed, indicating the need for sample-specific acceptance criteria (AC). The percent viable or percent apoptotic cells after thaw, as well as the functional ELISPOT response to PHA, were all effective when applied with limits as AC for separating samples damaged during storage from valid control samples. Although all three AC measures could be effectively applied, the apoptosis AC limit applied was best for separating samples that could respond to antigenic stimulation from samples that could not effectively respond.


* Corresponding author. Mailing address: WP26B-1144, Merck and Co., Inc., 770 Sumneytown Pike, West Point, PA 19486. Phone: (215) 652-3946. Fax: (215) 652-2142. E-mail: jeffrey_smith2{at}merck.com

{triangledown} Published ahead of print on 21 March 2007.


Clinical and Vaccine Immunology, May 2007, p. 527-537, Vol. 14, No. 5
1071-412X/07/$08.00+0     doi:10.1128/CVI.00435-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.